Denosumab versus zoledronic acid in elderly patients after hip fracture
Journal of Orthopaedic Surgery, 2022 Background Two injectable anti-osteoporosis medications, denosumab and zoledronic acid, have been widely used to treat patients with severe osteoporosis.
Seung-Ju Kim, Ji Woon Kim, Dong-Woo Lee
doaj +1 more source
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
JBMR Plus, 2020 Zoledronic acid is a bisphosphonate commonly used to treat bone diseases such as osteoporosis and cancer‐induced bone disease. Patients exhibit a variable sensitivity to zoledronic acid; the underlying explanation for this remains unclear.
Anaïs M J Møller +5 more
doaj +1 more source
Zoledronic acid inhibits the growth of leukemic MLL-AF9 transformed hematopoietic cells
Heliyon, 2020 A leukemic in vitro model produced by transducing Cord Blood derived-hematopoietic CD34+ cells with the MLL-AF9 translocation resulting in the oncogenic fusion protein, is used to assess for sensitivity to Zoledronic acid.
Emanuela Chiarella +9 more
doaj +1 more source
Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells. [PDF]
PLoS ONE, 2012 BACKGROUND: Zoledronic acid, one of the most potent nitrogen-containing biphosphonates, has been demonstrated to have direct anti-tumor and anti-metastatic properties in breast cancer in vitro and in vivo.
Yu-Guang Ma +10 more
doaj +1 more source
Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report
Journal of Medical Case Reports, 2011 Introduction Zoledronic acid is a highly effective treatment in Paget's disease for persistent bone pain and prevention of further progression of the disease. The commonest electrolyte abnormality is hypocalcemia. To the best of our knowledge this is the
Naysmith Morag +2 more
doaj +1 more source
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
Journal of Bone Oncology, 2014 Bone metastases represent common long term complications of patients with breast cancer. Zoledronic acid, an amino-bisphosphonate and mevalonate pathway inhibitor, is an established agent for the treatment of bone metastases.
Maria Wilke +8 more
doaj +1 more source
Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP [PDF]
, 2009 Peer ...
Rogers, Michael J. +11 more
core +1 more source
The Effects of Intravenous Zoledronic Acid in Chinese Women with Postmenopausal Osteoporosis
, 2012 The aim of this study was to assess the efficacy and safety of a once- yearly zoledronic acid treatment for Chinese women with postmenopausal osteoporosis in Taiwan and Hong Kong. This post hoc subpopulation analysis , from the Health Outcome and Reduced
黃兆山;秦凌霄;陳榮福;楊再興;陳博光;蔡克嵩;梁秉中 +1 more
core +1 more source
Anti-cancer activity of zoledronic acid in breast cancer
, 2009 Background: Zoledronic acid is used to prevent the bone loss associated with antioestrogen treatments in subjects with breast cancer. Preclinical studies suggest that zoledronic acid may have anticancer activity in its own right.
Doggrell, Sheila
core +1 more source
Prostate Cancer, 2011 Background. Loss of bone density with androgen deprivation therapy for prostate cancer is well recognized. We assessed the effects of quarterly infusion of zoledronic acid on bone mineral density (BMD) and markers of bone turnover over a one-year period ...
Anoop Kapoor +3 more
doaj +1 more source